According to a news release, cbdMD signed a multi-year exclusive agreement with Amify. Amify is a platform partner with Amazon that will allow cbdMD to list its CBD products on the e-commerce website.
However, YCBD won’t see the fruits of the deal with Amify just yet. Amazon currently doesn’t allow CBD products to be sold via its platform. Even so, that’s expected to change with growing interest in the products.
CbdMD notes that Amazon allowing CBD products would let it list a large collection of its goods on the store. That includes its gummies, tinctures, gelcaps, and topicals, as well as other products.
Martin Sumichrast, chairman and CEO of cbdMD, said the following about the deal boosting YCBD stock today.
“As an industry, this is the moment we’ve all been waiting for, and we believe we are close. When a global retailer like Amazon is ready to accept your products, you get your strategy prepared and perfected so you’re ready to go to market as soon as possible. That’s exactly what this partnership represents. We are already one of the largest online CBD businesses in America, and this distribution channel will play into our strength.”
YCBD stock is up 25.6% as of Monday morning.
There’s more hot stock market news to check out below!
We’ve got all the latest stock stories that traders need to know about for Monday. A few examples include what’s happening with shares of Novavax (NASDAQ:NVAX), Petros Pharmaceuticals (NASDAQ:PTPI), and NRx Pharmaceuticals (NASDAQ:NRXP) today. You can get all that info from the following links!
More Stock Market News for Monday
- NVAX Stock Is on Watch as Novavax Joins the Omicron Variant Battle
- PTPI Stock: The Short-Squeeze Buzz That Has Petros Pharmaceuticals Rocketing Today
- NRXP Stock Surges on Latest Covid-19 Update From NRx Pharmaceuticals
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed